Inhibitor Therapeutics Debt 2024

Inhibitor Therapeutics Aktienanalyse

What does Inhibitor Therapeutics do?

Inhibitor Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for cancer and autoimmune diseases. The company was founded in the USA in 2008 and has since established itself as a leading player in the biotech industry. The history of Inhibitor Therapeutics Inc began with the discovery of a promising molecule called ITI-007, which could represent a novel treatment option for schizophrenia. After extensive preclinical tests and clinical studies, ITI-007 was eventually approved by the FDA and brought to market. The medication has proven to be very successful and is used by many patients worldwide. Today, Inhibitor Therapeutics Inc's business model includes several different divisions. In addition to schizophrenia therapy, the company focuses on the development of innovative cancer therapies based on the blockage of enzymes and proteins responsible for tumor growth. The company utilizes a wide range of technologies to develop the best therapies for different types of cancer. Inhibitor Therapeutics Inc's products also include a range of diagnostics and biomarkers that contribute to the early detection and treatment of cancer. These technologies enable personalized medicine and help improve the effectiveness of therapies. Overall, the goal of Inhibitor Therapeutics Inc is to improve the lives of millions of people through groundbreaking innovations in cancer and autoimmune therapy. The company works closely with leading scientific institutions and clinics to translate the latest research findings into clinical practice. An important part of Inhibitor Therapeutics Inc's corporate culture is promoting diversity and inclusion. The company actively strives to create a work environment that is open and inclusive, where every employee has the opportunity to reach their full potential. Overall, Inhibitor Therapeutics Inc is an emerging company specializing in the development of innovative therapies for cancer and autoimmune diseases. With a wide range of technologies and products, a strong corporate culture, and a dedicated team of employees, the company is well-positioned to continue growing in the coming years and make its vision of better health for all a reality. Inhibitor Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Inhibitor Therapeutics's Debt Structure

Inhibitor Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Inhibitor Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Inhibitor Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Inhibitor Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Inhibitor Therapeutics Stock

What is the debt of Inhibitor Therapeutics this year?

Inhibitor Therapeutics has a debt level of -8.84 USD this year.

What was the debt of Inhibitor Therapeutics compared to the previous year?

The debt of Inhibitor Therapeutics has increased by -23.4% compared to the previous year dropped.

What are the consequences of high debt for investors in Inhibitor Therapeutics?

High debt can pose a risk for investors of Inhibitor Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Inhibitor Therapeutics?

Low debt means that Inhibitor Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Inhibitor Therapeutics affect the company?

An increase in debt of Inhibitor Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Inhibitor Therapeutics affect the company?

A reduction in debt of Inhibitor Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Inhibitor Therapeutics?

Some factors that can influence the debt of Inhibitor Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Inhibitor Therapeutics so important for investors?

The debts of Inhibitor Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Inhibitor Therapeutics take to change the debt?

To change the debt, Inhibitor Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Inhibitor Therapeutics pay?

Over the past 12 months, Inhibitor Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibitor Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Inhibitor Therapeutics?

The current dividend yield of Inhibitor Therapeutics is .

When does Inhibitor Therapeutics pay dividends?

Inhibitor Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inhibitor Therapeutics?

Inhibitor Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Inhibitor Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inhibitor Therapeutics located?

Inhibitor Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inhibitor Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inhibitor Therapeutics from 5/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/29/2024.

When did Inhibitor Therapeutics pay the last dividend?

The last dividend was paid out on 5/29/2024.

What was the dividend of Inhibitor Therapeutics in the year 2023?

In the year 2023, Inhibitor Therapeutics distributed 0 USD as dividends.

In which currency does Inhibitor Therapeutics pay out the dividend?

The dividends of Inhibitor Therapeutics are distributed in USD.